Indeed, recently developed MFN2 agonists reversing mitochondrial defects in a Charcot-Marie-Tooth disease type 2A model51 also rescued CHCHD10S59L-induced morphologic and functional mitochondrial defects (Fig. 7b, c and Supplementary Fig. 7d, e). Here, MFN2 is linked to Charcot-Marie-Tooth disease type 2A1.